Effective results with botulinum toxin in cerebral palsy.

This study evaluated the improvement in clinical measures and quality of life (QOL) among patients with cerebral palsy treated with botulinum toxin type A. Fifty-seven parents of cerebral palsy patients who used botulinum toxin during the time of the study were enrolled. The QOL questionnaires included the following: Child Caregiver Questionnaire, Pediatrics Outcomes Data Collection Instrument, and clinical evaluations. The questionnaires were administered before the first use of botulinum toxin and approximately 1 year later, a mean interval of 13.8 months. Treatment resulted in clinical improvement in tone, upper limb function, and Gross Motor Function Classification System score. Better outcomes were observed in patients younger than 6.5 years. QOL questionnaires revealed a tendency toward improvement in the comfort dimension of the Child Caregiver Questionnaire as well as in the upper extremities and physical functions, transfers and basic mobility, and global function and symptom of the Pediatrics Outcomes Data Collection Instrument. The QOL measures correlated with clinical evaluations. Patients with low cognitive ability and refractory epilepsy had the worst results. Children and adolescents have reduced spasticity and experience good results in the clinical measurements and in QOL after treatment with botulinum toxin.

Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A.

Primary palmar hyperhidrosis in children and adolescents may be severe enough to affect school and physical activities, causing emotional problems, stress in the patient's life, and a compromised quality of life. Nine patients with palmar hyperhidrosis underwent treatment with botulinum A. Before the session, and in the 1-, 3-, 6-, 9-, and 12-month post-session follow-ups, the patients were administered the Minor test, gravimetry, the Scales of Frequency and Severity, and the Questionnaire of Quality of Life. The mean age was 11 years, with seven girls and two boys. Each patient was administered at least one treatment of botulinum toxin in the palm of the hands (75-150 U for palm), with the mean number of sessions 2.2 (range: 1-4). All sessions in the patients resulted in drying of the hands, with a mean duration of effect of 7 months. Botulinum toxin A controls excessive sweat in the palms of children and adolescents who have primary palmar hyperhidrosis, with an improvement in the quality of life. The therapy is safe and effective in this pediatric group and can be considered before surgical interventions.

Neurofibromatosis 1 associated with spinal muscular atrophy.

Neurofibromatosis type 1, or von Recklinghausen disease, is a progressive, autosomal dominant, monogenic disease. Spinal muscular atrophy is a progressive, autosomal recessive, monogenic disease. Specific anti-polysaccharide antibody deficiency is an immune disorder suspected in any child older than 2 years who suffers from recurrent respiratory tract infections or in patients with unusually severe complications from infections under appropriate treatment. Reported here is the coinheritance of two monogenic syndromes in the same patient, a novel association with specific anti-polysaccharide antibody deficiency.